Day: November 26, 2024

Continuous variables were compared by the use of the Student’s two-tailed = 111; 68.5%) and 18.5% (30/162) had moderate or high disease activity at the time of illness (Table 1 and Supplementary Table S1). 0.001) and tocilizumab (OR 0.147, 95% CI 0.053C0.408, < 0.001) had reduced odds of illness. Further, TNFi tended to become protecting […]